Abstract
Background: Natural products have been universally approached in the research of novel trends useful to detail the essential paths of the life sciences and as a strategy for pharmacotherapeutics.
Objective: This work focuses on further modification to the 6-hydroxy-flavanone building block aiming to obtain improved BCR-ABL kinase inhibitors.
Methods: Ether derivatives were obtained from Williamson synthesis and triazole from Microwave- assisted click reaction. Chemical structures were finely characterized through IR, 1H and 13C NMR and HRMS. They were tested for their inhibitory activity against BCR-ABL kinase.
Results: Two inhibitors bearing a triazole ring as a pharmacophoric bridge demonstrated the strongest kinase inhibition at IC50 value of 364 nM (compound 3j) and 275 nM (compound 3k).
Conclusion: 6-hydroxy-flavanone skeleton can be considered as a promising core for BCR-ABL kinase inhibitors.
Keywords: Semisynthesis, Triazole, BCR-ABL kinase inhibitors, Chronic myeloid leukemia, Williamson synthesis, 6-hydroxy-flavanone skeleton.
Graphical Abstract
Current Topics in Medicinal Chemistry
Title:Flavonoid Derivatives Targeting BCR-ABL Kinase: Semisynthesis, Molecular Dynamic Simulations and Enzymatic Inhibition
Volume: 21 Issue: 22
Author(s): Rayssa Ribeiro, Mariana A. Eloy, Carla S. Francisco, Clara L. Javarini, Gabriela M. Ayusso, Victor Da Rocha Fonseca, Wanderson Romão, Luis O. Regasini, Sheila C. Araujo, Michell O. Almeida, Kathia M. Honorio, Heberth de Paula, Valdemar Lacerda *Pedro A. B. Morais
Affiliation:
- Programa de Pos-Graduacao em Quimica, Universidade Federal do Espirito Santo, 29075910, Vitoria- ES,Brazil
Keywords: Semisynthesis, Triazole, BCR-ABL kinase inhibitors, Chronic myeloid leukemia, Williamson synthesis, 6-hydroxy-flavanone skeleton.
Abstract:
Background: Natural products have been universally approached in the research of novel trends useful to detail the essential paths of the life sciences and as a strategy for pharmacotherapeutics.
Objective: This work focuses on further modification to the 6-hydroxy-flavanone building block aiming to obtain improved BCR-ABL kinase inhibitors.
Methods: Ether derivatives were obtained from Williamson synthesis and triazole from Microwave- assisted click reaction. Chemical structures were finely characterized through IR, 1H and 13C NMR and HRMS. They were tested for their inhibitory activity against BCR-ABL kinase.
Results: Two inhibitors bearing a triazole ring as a pharmacophoric bridge demonstrated the strongest kinase inhibition at IC50 value of 364 nM (compound 3j) and 275 nM (compound 3k).
Conclusion: 6-hydroxy-flavanone skeleton can be considered as a promising core for BCR-ABL kinase inhibitors.
Export Options
About this article
Cite this article as:
Ribeiro Rayssa , Eloy A. Mariana , Francisco S. Carla , Javarini L. Clara , Ayusso M. Gabriela , Da Rocha Fonseca Victor, Romão Wanderson, Regasini O. Luis , Araujo C. Sheila , Almeida O. Michell, Honorio M. Kathia , de Paula Heberth , Lacerda Valdemar *, Morais A. B. Pedro , Flavonoid Derivatives Targeting BCR-ABL Kinase: Semisynthesis, Molecular Dynamic Simulations and Enzymatic Inhibition, Current Topics in Medicinal Chemistry 2021; 21 (22) . https://dx.doi.org/10.2174/1568026621666210705170047
DOI https://dx.doi.org/10.2174/1568026621666210705170047 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The 2010 Patent Landscape for Spleen Tyrosine Kinase Inhibitors+
Recent Patents on Inflammation & Allergy Drug Discovery Modification of Lifestyle Factors are Needed to Improve the Metabolic Health of Patients with Cardiovascular Disease Risk
Current Pharmaceutical Design Patients Stratification Strategies to Optimize the Effectiveness of Scavenging Biogenic Aldehydes: Towards a Neuroprotective Approach for Parkinson's Disease
Current Neuropharmacology Drug-induced Inhibition and Trafficking Disruption of ion Channels: Pathogenesis of QT Abnormalities and Drug-induced Fatal Arrhythmias
Current Cardiology Reviews Combinations of Plant Polyphenols & Anti-Cancer Molecules: A Novel Treatment Strategy for Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Conference Report (3<sup>rd</sup> GTC Congress Report on Ubiquitin & Drug Discovery Feb 25-26, Palms Casino Resort, Las Vegas, NV, USA)
CNS & Neurological Disorders - Drug Targets Aldose Reductase Enzyme and its Implication to Major Health Problems of the 21st Century
Current Medicinal Chemistry Physicochemical Strategies for Inhibition of Amyloid Fibril Formation: An Overview of Recent Advances
Current Medicinal Chemistry Are the Antioxidant Properties of Carvedilol Important for the Protection of Cardiac Mitochondria?
Current Vascular Pharmacology Inflammatory Mechanisms of Adverse Reactions to Drug-Eluting Stents
Current Vascular Pharmacology Poly-Pharmacy Among the Elderly: Analyzing the Co-Morbidity of Hypertension and Diabetes
Current Pharmaceutical Design New Target Molecules in the Drug Control of Blood Pressure and Circulation
Current Drug Targets - Cardiovascular & Hematological Disorders Tackling Chronic Pain and Inflammation through the Purinergic System
Current Medicinal Chemistry Retracted: Potential Health Benefits of Broccoli- A Chemico-Biological Overview
Mini-Reviews in Medicinal Chemistry Endothelial Cells in Inflammation and Angiogenesis
Current Drug Targets - Inflammation & Allergy Tyrosine Kinases and Inflammatory Signalling
Current Molecular Medicine Silibinin – A Promising New Treatment for Cancer
Anti-Cancer Agents in Medicinal Chemistry Tubulin Colchicine Binding Site Inhibitors as Vascular Disrupting Agents in Clinical Developments
Current Medicinal Chemistry Current Options and Perspectives in the Treatment of Diabetic Neuropathy
Current Pharmaceutical Design Multiple-modified Low-Density Lipoprotein as Atherogenic Factor of Patients' Blood: Development of Therapeutic Approaches to Reduce Blood Atherogenicity
Current Pharmaceutical Design